GSA Capital Partners LLP Grows Stake in Versartis Inc (VSAR)

GSA Capital Partners LLP increased its position in shares of Versartis Inc (NASDAQ:VSAR) by 78.5% during the second quarter, HoldingsChannel.com reports. The firm owned 284,700 shares of the biopharmaceutical company’s stock after buying an additional 125,200 shares during the period. GSA Capital Partners LLP’s holdings in Versartis were worth $577,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Spark Investment Management LLC increased its position in shares of Versartis by 88.6% during the second quarter. Spark Investment Management LLC now owns 176,500 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 82,900 shares during the period. LMR Partners LLP bought a new stake in shares of Versartis during the second quarter valued at approximately $162,000. Acadian Asset Management LLC increased its position in shares of Versartis by 71.4% during the second quarter. Acadian Asset Management LLC now owns 83,064 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 34,607 shares during the period. A.R.T. Advisors LLC bought a new stake in shares of Versartis during the first quarter valued at approximately $147,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Versartis by 13.6% during the first quarter. Dimensional Fund Advisors LP now owns 617,702 shares of the biopharmaceutical company’s stock valued at $1,019,000 after purchasing an additional 73,754 shares during the period. Institutional investors and hedge funds own 38.64% of the company’s stock.

Shares of VSAR stock opened at $1.45 on Friday. The company has a current ratio of 16.99, a quick ratio of 16.99 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $56.17 million, a P/E ratio of -0.60 and a beta of 1.91. Versartis Inc has a one year low of $1.35 and a one year high of $22.10.



Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.96) by $0.69. research analysts expect that Versartis Inc will post -3.15 earnings per share for the current fiscal year.

Separately, ValuEngine upgraded Versartis from a “hold” rating to a “buy” rating in a research report on Monday, August 13th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $5.13.

About Versartis

See Also: Should You Consider an Index Fund?

Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis Inc (NASDAQ:VSAR).

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply